Confusion Abounds For Big Pharma After EU Astra Ruling

Law360, New York (July 12, 2010, 9:17 PM EDT) -- A recent court decision trimming a European Commission's €60 million fine against AstraZeneca PLC for abuse of dominance leaves the drug industry little wiser when it comes to navigating the European Union's regulations governing pharmaceutical companies and its competition law, experts say.

In its July 1 ruling -- which could set the pharmaceutical giant up for an appellate court showdown with the regulator -- the EU General Court found that even though the EC had not proven that AstraZeneca's decision to deregister the marketing approvals for...
To view the full article, register now.